(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 September 2012 (27.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/128587 A2

(51) International Patent Classification:
A61K 9/28 (2006.01) *A61K 47/48* (2006.01)
A61K 9/48 (2006.01) *A61K 31/20* (2006.01)

(21) International Application Number:
PCT/KR2012/002134

(22) International Filing Date:
23 March 2012 (23.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2011-0025940 23 March 2011 (23.03.2011) KR
10-2011-0041168 29 April 2011 (29.04.2011) KR

(71) Applicant *(for all designated States except US)*: **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-910 (KR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIM, Yong Il** [KR/KR]; Jinheung Apt. 147-2201, Hwaseo-dong, Paldal-gu, Suwon-si, Gyeonggi-do 442-150 (KR). **YOON, Eun Jin** [KR/KR]; Cheoncheon Prugio Apt. 101-902, Cheoncheon-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR). **IM, Ho Taek** [KR/KR]; Samsung Raemian 1-cha Apt. 117-1204, Mabuk-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-557 (KR). **SHIN, Yoon Sub** [KR/KR]; Samsung Raemian Apt. 109-1304, Cheoncheon-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-723 (KR). **PARK, Jae Hyun** [KR/KR]; Dongsin Apt. 311-404, Cheongmyeongmaeul, Youngtong-dong, Youngtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). **WOO, Jong Soo** [KR/KR]; Cheoncheon Prugio Apt. 120-2303, Cheoncheon-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR).

(74) Agent: **FIRSTLAW P.C.**; Trust Tower, 275-7 Yang-jae-Dong, Seocho-Ku, Seoul 137-739 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: ORAL COMPLEX COMPOSITION COMPRISING OMEGA-3 FATTY ACID ESTER AND HMG-COA REDUCTASE INHIBITOR

FIG. 4



(57) Abstract: An oral complex composition comprising omega-3 fatty acid esters and HMG-CoA reductase inhibitor, can effectively raise serum HDL level while reducing serum LDL and TG levels and can be used to treat hyperlipidemia owing to its good drug dissolution rate and storage stability with showing no delayed release behavior even after 6 months of accelerated storage.

WO 2012/128587 A2